Copyright © 2003 by the European Society of Cardiology.
Regular Articles
LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock
A prospective randomized study
a The Cardiology Department, Assaf-Harofeh Medical Center, Zerifin, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
b Department of Medicine "A", Assaf-Harofeh Medical Center, Zerifin, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
* Corresponding author. Gad Cotter M.D., The Cardiology Department, Assaf-Harofeh Medical Center, 70300 Zerifin Israel. Tel.: +972-8-9779778; fax: +972-8-9779779
E-mail address: cotterg{at}hotmail.com
Received 7 October 2002; revised 16 February 2003; accepted 13 March 2003
Aims To evaluate the effect of L-NAME (a nitric oxide syntahse inhibitor) in the treatment of refractory cardiogenic shock.
Methods and results We enrolled 30 consecutive patients with refractory cardiogenic shock (systolic blood pressure that deteriorated progressively to <100mmHg during an acute coronary syndrome despite maximal percutaneous coronary revascularization, intra aortic balloon pump, and IV dopamine, furosemide and fluids treatment for at least 1h, accompanied by signs of peripheral hypoperfusion). Patients were randomized to supportive care alone (n=15, control group) or to supportive care in addition to L-NAME (1mg/Kg bolus and 1mg/Kg/h continuous IV drip for 5h n=15).
Death at one month was 27% in the L-NAME group vs. 67% in the control group (p=0.008). Unaugmented mean arterial blood pressure at 24 h from randomization was 86±20mmHg in the L-NAME group vs. 66±13mmHg in the control group (p=0.004). Urine output increased at 24h by 135±78cc/h in the L-NAME group vs a decrease of 12±87cc/h in the control group (p<0.001). Time on IABP and time on mechanical ventilation were significantly shorter in the L-NAME group.
Conclusions The results of the present study further support our previous observation that NO synthase inhibitors are beneficial in the treatment of patients with refractory cardiogenic shock.
Key Words: Cardiogenic Shock • Nitric-Oxide • NO synthase inhibitors
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Cardiogenic shock: have we really found the magic potion?
- Venu Menon
EHJ 2003 24: 1279-1281.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. DelFraino, V. Dzavik, O. W. Griffith, D. Hathaway, J. A. Panza, S. E. Nissen, et al. Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction Circulation, November 13, 2007; 116(20): 2315 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, J. H. Alexander, J. S. Hochman, H. R. Reynolds, V. Dzavik, and F. J. Van de Werf Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock Reply JAMA, September 5, 2007; 298(9): 972 - 973. [Full Text] [PDF]
|
|
|
|
|
|
T. Teerlink Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock JAMA, September 5, 2007; 298(9): 971 - 972. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Dzavik, G. Cotter, H. R. Reynolds, J. H. Alexander, K. Ramanathan, A. L. Stebbins, D. Hathaway, M. E. Farkouh, E. M. Ohman, D. A. Baran, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study Eur. Heart J., May 1, 2007; 28(9): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ndrepepa, A. Schomig, and A. Kastrati Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock: Looking for the Reasons JAMA, April 18, 2007; 297(15): 1711 - 1713. [Full Text] [PDF]
|
|
|
|
|
|
The TRIUMPH Investigators Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial JAMA, April 18, 2007; 297(15): 1657 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Zannad, A. Mebazaa, Y. Juilliere, A. Cohen-Solal, L. Guize, F. Alla, P. Rouge, P. Blin, M.-H. Barlet, L. Paolozzi, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study Eur J Heart Fail, November 1, 2006; 8(7): 697 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. George, G.-H. Yi, A. R. Schulman, B. T. Morrow, Y. Cheng, A. Gu, G. Zhang, M. C. Oz, D. Burkhoff, and J. Wang A polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1126 - H1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sengupta, L. Dhawan, P G L Lalitkumar, and D Ghosh Nitric oxide in blastocyst implantation in the rhesus monkey Reproduction, September 1, 2005; 130(3): 321 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kohsaka, V. Menon, A. M. Lowe, M. Lange, V. Dzavik, L. A. Sleeper, J. S. Hochman, and for the SHOCK Investigators Systemic Inflammatory Response Syndrome After Acute Myocardial Infarction Complicated by Cardiogenic Shock Arch Intern Med, July 25, 2005; 165(14): 1643 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Duvernoy and E. R. Bates Management of Cardiogenic Shock Attributable to Acute Myocardial Infarction in the Reperfusion Era J Intensive Care Med, July 1, 2005; 20(4): 188 - 198. [Abstract] [PDF]
|
|
|
|
|
|
H. Thiele, P. Sick, E. Boudriot, K.-W. Diederich, R. Hambrecht, J. Niebauer, and G. Schuler Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock Eur. Heart J., July 1, 2005; 26(13): 1276 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A G C Sutton, P Finn, J A Hall, A A Harcombe, R A Wright, and M A de Belder Predictors of outcome after percutaneous treatment for cardiogenic shock Heart, March 1, 2005; 91(3): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Jones, J. J. M. Greer, P. D. Ware, J. Yang, K. Walsh, and D. J. Lefer Deficiency of iNOS does not attenuate severe congestive heart failure in mice Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H365 - H370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Finally, a Treatment for Cardiogenic Shock? Journal Watch Emergency Medicine, September 24, 2003; 2003(924): 1 - 1. [Full Text]
|
|
|
|
|
|
V. Menon Cardiogenic shock: have we really found the magic potion? Eur. Heart J., July 2, 2003; 24(14): 1279 - 1281. [Full Text] [PDF]
|
|